Diarrhea Caused by Proton Pump Inhibitor Administration: Comparisons Among Lansoprazole, Rabeprazole, and Omeprazole

Current Therapeutic Research - Clinical and Experimental

Volumn 73, Issue 3, 2012, Pages 112-120

  Shimura, Shino ^a   Hamamoto, Naoharu ^b   Yoshino, Nagisa ^c   Kushiyama, Yoshinori ^d   Fujishiro, Hirofumi ^e   Komazawa, Yoshinori ^f   Furuta, Kenji ^a   Ishihara, Shunji ^a   Adachi, Kyoichi ^a   Kinoshita, Yoshikazu ^a  

^a SHIMANE UNIVERSITY   (Japan)

^b Hamamoto Clinic   (Japan)

^c Yoshino Clinic   (Japan)

^d MATSUE RED CROSS HOSPITAL   (Japan)

^e SHIMANE PREFECTURAL CENTRAL HOSPITAL   (Japan)

^f Izumo City General Medical Center   (Japan)

Author keywords

Adverse effect; Collagenous colitis; Diarrhea; Loose bowels; Proton pump inhibitor

Indexed keywords

ACETYLSALICYLIC ACID; LANSOPRAZOLE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; RABEPRAZOLE;

ADULT; AGED; ARTICLE; BRISTOL STOOL SCALE FORM; COLONOSCOPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG MEGADOSE; FECES COMPOSITION; FEMALE; GASTROESOPHAGEAL REFLUX; HISTOPATHOLOGY; HUMAN; INCIDENCE; LOOSE FECES; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PRIORITY JOURNAL; QUALITY OF LIFE; STOMACH DISEASE; TREATMENT DURATION;

EID: 84861807681     PISSN: 0011393X     EISSN: 18790313     Source Type: Journal    
DOI: 10.1016/j.curtheres.2012.03.002     Document Type: Article

References (25)

1. Mishima I., Adachi K., Arima N., et al. Prevalence of endoscopically negative and positive gastroesophageal reflux disease in the Japanese. Scand J Gastroenterol 2005, 40:1005-1009.
2. Fujishiro H., Adachi K., Kawamura A., et al. Influence of Helicobacter pylori infection on the prevalence of reflux esophagitis in Japanese patients. J Gastroenterol Hepatol 2001, 16:1217-1221.
3. Ootani H., Iwakiri R., Shimada R., et al. Role of Helicobacter pylori infection and nonsteroidal anti-inflammatory drug use in bleeding peptic ulcers in Japan. J Gastroenterol 2006, 41:41-46.
4. Shiotani A., Kamada T., Haruma K. Low-dose aspirin-induced gastrointestinal diseases: past, present, and future. J Gastroenterol 2008, 43:581-588.
5. Thomson A.B.R., Sauve M.D., Kassam N., Kamitakahara H. Safety of the long-term use of proton pump inhibitors. World J Gastroenterol 2010, 16:2323-2330.
6. Umeno J., Matsumoto T., Nakamura S., et al. Linear mucosal defect may be characteristic of lansoprazole-associated collagenous colitis. Gastrointest Endosc 2008, 67:1185-1191.
7. de la Iglesia Fanjul I., de Castro Losa M.R., Izquierdo García F. Collagenous colitis. Clinicopathological study of 18 cases [in Spanish, Abstract in English]. Revista Clin Espaola 2007, 207:394-398.
8. Keszthelyi D., Jansen S.V., Schouten G.A., et al. Proton pump inhibitor use is associated with an increased risk for microscopic colitis: a case-control study. Aliment Pharmacol Ther 2010, 32:1124-1128.
9. Hilmer S.N., Heap T.R., Eckstein R.P., et al. Microscopic colitis associated with exposure to lansoprazole. Med J Aust 2006, 184:185-186.
10. Williams J.J., Beck P.L., Andrews C.N., et al. Microscopic colitis-common cause of diarrhoea in older adults. Age Ageing 2010, 39:162-168.
11. Pilotto A., Franceschi M., Vitale D., et al. The prevalence of diarrhea and its association with drug use in elderly outpatients: a multicenter study. Am J Gastroenterol 2008, 103:2816-2823.
12. Gangarosa R.E., Glass R.I., Lew J.F., Borning J.R. Hospitalizations involving gastroenteritis in the United States, 1985: the special burden of the disease among the elderly. Am J Epidemiol 1992, 135:281-290.
13. Shinozaki M., Fukudo S., Hongo M., et al. High prevalence of irritable bowel syndrome in medical outpatients in Japan. J Clin Gastroenterol 2008, 42:1010-1016.
14. Christoph H., Heinz F.H., Guenter J.K., Emil C.R. Mechanisms and management of antibiotic-associated diarrhea. Clin Infect Dis 1998, 27:702-710.
15. Reilly J.P. Safety profile of the proton-pump inhibitors. Am J Health Syst Pharm 1999, 56:11-17.
16. Edwards I.R., Aronson J.K. Adverse drug reactions: definitions, diagnosis, and management. Lancet 2000, 356:1255-1259.
17. Martin R.M., Dunn N.R., Freemantle S., Shakir S. The rates of common adverse events reported during treatment with proton pump inhibitors used in general practice in England: cohort studies. Br J Clin Pharmacol 2000, 50:366-372.
18. Berardi R.R. A critical evaluation of proton pump inhibitors in the treatment of gastroesophageal reflux disease. Am J Manag Care 2000, 6:491-505.
19. Dial S., Delaney J.A., Barkun A.N., Suissa S. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA 2005, 294:2989-2995.
20. García Rodríguez L.A., Ruigómez A., Panés J. Use of acid-suppressing drugs and the risk of bacterial gastroenteritis. Clin Gastroenterol Hepatol 2007, 5:1418-1423.
21. Takahashi Y., Sakai H., Kuragari M., et al. Expression of ATP1AL1, a non-gastric proton pump, in human colorectum. Jpn J Physiol 2002, 52:317-321.
22. Freston J.W., Rose P.A., Heller C.A., et al. Safety profile of lansoprazole: The US Clinical Trial Experience. Drug Saf 1999, 20:195-205.
23. Freston J.W., Hisada M., Peura D.A., et al. The clinical safety of long-term lansoprazole for the maintenance of healed erosive oesophagitis. Aliment Pharmacol Ther 2009, 29:1249-1260.
24. Galmiche J.P., Hatlebakk J., Attwood S., et al. Laparoscopic Antireflux Surgery vs Esomeprazole Treatment for Chronic GERD: The LOTUS Randomized Clinical Trial. JAMA 2011, 305:1969-1977.
25. Chande N., David K.D. Microscopic colitis associated with lansoprazole: report of two and a review of the literature. Scand J Gastroenterol 2007, 42:530-533.